EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the Board appointment of David Lawrence as an independent Non-Executive Director. Mr. Lawrence is an accomplished executive with over 30 years of experience in finance, M&A, business development and corporate strategy in the life sciences industry. Dr James McIlroy, CEO at EnteroBiotix, said: “I am excited that David is joining our Board. He is highly experienced and successful with deep capital markets expertise...